PDL BiopharmaPDLI
13F holders, Q4 2025 (December 31)9holders +1
1new positions
1sold out
$0.15avg. 13F price*
At the end of Q4 2025, 9 institutions reported holding PDL Biopharma Inc. (PDLI) in their 13F filings, up 1 from Q3 2025. 1 opened new positions and 1 sold out. The largest holders were Diversified Trust Co. ($26K), Rhumbline Advisers ($2K) and Hancock Whitney Corp. ($0).
- Company
- PDL Biopharma Inc.
- CUSIP
- 69329Y104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 875 shares bought and 8,064 shares sold, net −7,189 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Diversified Trust Co. | 0.00% | No change | 11,029 | $26K |
| Rhumbline Advisers | 0.00% | No change | 612 | $2K |
| Hancock Whitney Corp. | 0.00% | No change | 128,394 | $0 |
| Westside Investment Management, Inc. | 0.00% | No change | 500 | $0 |
| Argent Trust Co | 0.00% | No change | 41,405 | $0 |
| Financial Gravity Asset Management, Inc. | 0.00% | No change | 33 | $0 |
| Wellington-Altus USA Inc. | 0.00% | — | 275 | $0 |
| Motiv8 Investments LLC | 0.00% | New | 875 | $0 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 100 | $0 |
"% of holder's portfolio" is PDLI's weight in each manager's 13F, not the share of PDL Biopharma Inc. the manager owns.